 |
 |
Rick Hansen wrote... > Hello, > > I am very interested in finding out more information on the current status of > the research being done with GPI-1046 by Guilford Pharmaceuticals of > Baltimore, Maryland and Amgen. Does anyone know of someone who may be > involved in the clinical trials for this drug? The trials on human subjects > were scheduled to start the latter part of this year. > > Thank you, > > Rick Hansen Hi Rick and all, I looked up GPI-1046 using the free WebFerret and found a lot of very interesting background reading... (Scroll to the bottom for latest info on trials...) I believe GPI stands for Guilford Pharmaceuticals Inc. Raw Nerve OHSU researcher Bruce Gold took what might be the first step in reversing paralysis. So why is someone else walking away with the glory and the money? http://www.wweek.com/html/covera052098.html Bruce Gold http://www.ohsu.edu/som-CellBio/faculty/gold.html Research Results of Guilford's Neuroimmunophilin Ligands Published in Proceedings of the National Academy of Sciences Tuesday, March 04, 1997 http://pages.prodigy.com/A/L/D/ALSPROD/prodtran.htm Pill Stimulates CNS Neurons' Regrowth Psychiatric Times April 1997 http://www.mhsource.com/pt/p970401a.html New drug may reverse symptoms of Parkinson's April 9, 1997 http://www.cnn.com/HEALTH/9704/09/nfm/parkinsons/ On April 10, 1997, the Executive Director of NPF, Mr. Emilio Alonso-Mendoza was interviewed by various news services regarding the recent announcement of a drug, GPI-1046, which could possibly reverse Parkinson's disease. http://www.parkinson.org/cureqna.htm A drug now in development could benefit those with Parkinson's disease, according to scientists who presented their findings April 15th. 1997 at the American Chemical Society meeting in San Francisco. http://www.sd-pc.com/gpi1046.html Neuroimmunophilin Ligands August 21, 1997 http://www.heskco.com/karan/pages/newbna.htm Guilford Reports Brain Cell Regeneration Date: Wed, 24 Sep 1997 http://web.missouri.edu/~psycmm/abnormal/msg00208.html Small Molecule Neurotrophins: NI October 1997 http://www.neuroinv.com/neurotrophins.html Parkinson's Disease Research Treatments GPI-1046 Sheraton Midway Hotel; April 26, 1998 http://www.clinical-services.med.umn.edu/movement-disorders/tuite-talk.htm Guildford Pharmaceuticals Announces 2nd. Quarter Results Thu, 16 Jul 98 http://www.iii.co.uk/newsfeed/98/07/16/RESULTS_Guilford-002.shtml Guilford Pharmaceuticals Inc · 10-K · For 12/31/98 http://www.secinfo.com/dsvRq.61Ze.htm GPI-1046 and compounds similar to it are also being developed as growth factors to help patients with PD. It is possible that this treatment will be studied in research trials in humans (in 1999 or 2000) to see if it can restore function in PD http://www.clinical-services.med.umn.edu/movement-disorders/park3.htm What is GPI-1046? Can it possibly reverse Parkinson's disease? (March 1999) http://www.parkinsonsmi.org/newsletter/faqs/experts.html GPI-1046: Promise of Reversing Parkinson’s (March 24th. 1999) http://www.nwpf.org/news/item990324a.html Society for Neuroscience 29th Annual Meeting (23-28 October 1999), Miami Beach, FL, USA GPI-1046 http://www.current-drugs.com/NEWS/NEUROR1.htm GPI-1046 This compound has the unique property that it can regenerate dead neurons in the brain http://www.indobuzz.com/pdfi/news3.htm Neuroimmunophilin Publications Abstracts from 1999 Society for Neuroscience http://www.guilfordpharm.com/b_p_neuro_i.htm A still-unnamed compound, GPI-1046, developed by the California-based biotech firm Amgen, has just begun testing in humans. In animal models, GPI stimulated cells to repair damage in the substantia nigra. "There is hope that this compound could treat the basic degenerative process itself," says Lieberman. (Nov. 23, 1999) http://www.usatoday.com/life/health/doctor/lhdoc037.htm Solomon H. Snyder http://ww2.med.jhu.edu/pharmacology/pages/faculty/snyder.html GPI-1046, The First Oral Drug to Stimulate Re-Growth of Damaged Dopamine Nerve Cells in an Animal Model of Parkinson Disease January 7th. 2000 By Abraham Lieberman from press releases of Guilford Pharmaceuticals and Amgen. http://www.parkinson.org/texthtms/tamgen.htm April 2000 Cell growth stimulators - GPI-1046, still so new it doesn't have a trade name, stimulates cell growth in the substantia nigra, a small area of the midbrain critical to the production of dopamine. The newer NIL-A, "offers more promise," says Bornstein. http://www.usatoday.com/life/health/doctor/lhdoc135.htm May 2, 2000— GPI-1046, The First Oral Drug to Stimulate Re-Growth of Damaged Dopamine Nerve Cells in an Animal Model of Parkinson Disease http://www.nwpf.org/news/item20000508a.html http://www.egroups.com/message/nwpf-update/79 Winter T, Zimmermann M, Bürger E, Eickmeier C, Herdegen T. The immunophilin-ligand FK506, but not GPI-1046, protects against neuronal death and inhibits c-Jun expression in substantia nigra pars compacta following transection of the rat medial forebrain bundle. Neuroscience 2000;95:753-762. http://www.uni-kiel.de/Pharmakologie/publikat.htm Neuroimmunophilin Ligands – Parkinson’s Disease Guilford has partnered the neuroimmunophilin program for nerve regeneration in neurological disorders with Amgen, Inc. Amgen is responsible for all clinical trials. This program includes the prototype compound GPI-1046 and the clinical lead compound, NIL-A. The initial disease target is Parkinson’s disease. Amgen has completed Phase I testing and Guilford anticipates that Phase II development will proceed in Parkinson’s patients in the second half of 2000. For more information on this program, or to enquire about enrolling in a clinical study, please contact Amgen at (1-800-772-6436) If you are calling from outside the United States, please call (805) 447-1954 http://www.guilfordpharm.com/b_patient.htm I try to make a difference ...... murray [log in to unmask] View the Parkinson's Awareness Links at: http://www.geocities.com/janet313/pienet/wwweb/index.html